Table 1 Patient characteristics
No. patients | 31 |
|---|---|
Gender, Male, n (%) | 20 (65) |
Age years, mean (SD) | 59.6 (17.6) |
BMI, mean (SD) | 26.3 (4.0) |
Asymptomatic, n (%) | 29 (90) |
MEN1 syndrome, n (%) | 7 (23) |
CgA, n (%) | |
Strongly positive | 3 (10) |
Weakly positive | 15 (48) |
Negative | 13 (42) |
PP (pmol/L), median (IQR) | 68 (41–129) |
5-HIAA (nmol/L), median (IQR) | 64 (53–64) |
Primary tumor size (mm) | |
All patients, median (IQR) | 24 (14–35) |
Operated, median (IQR) (n = 20) | 31 (20–52) |
Biopsy and follow-up, median (min–max) (n = 2) | 24 (22–25) |
Follow-up*, median (IQR) (n = 9) | 14 (13–21) |
Tumor localization, n (%) | |
Head | 12 (39) |
Body | 2 (6) |
Tail | 10 (32) |
Multiple | 7 (23) |
Treatment, n (%) | |
Surgery | 20 (65) |
Biopsy and follow-up | 2 (6) |
Follow-up* | 9 (29) |
Type of surgery, n (%) | |
Total pancreatectomy | 2 (10) |
Pancreaticoduodenectomy | 4 (20) |
Distal pancreatectomy | 13 (65) |
Enucleation | 1 (5) |
Type of surgery, n (%) | |
Open | 13 (75) |
Laparoscopic | 5 (25) |
Robotic surgery | 2 (10) |
Grade, n (%) | |
G1 | 13 (59) |
G2 | 8 (36) |
G3 NET | 1 (5) |
G3 NEC | 0 |